Principal Investigator

Guido Erwin Michael
Awardee Organization

University Of California Los Angeles
United States

Fiscal Year
Activity Code
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma

The Program Project Grant “Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma” constitutes a highly collaborative, multidisciplinary research program designed to make a significant impact on the investigation of obesity in the development of pancreatic cancer. A detailed understanding of the biological mechanisms of action of obesity on pancreatic cancer development can form the rationale for biologically-based practices, scientifically-founded recommendations and interventional strategies in the prevention of this disease. The Program Project includes expertise from the UCLA campus and Cedars Sinai Medical Center. The Program is led by experienced pancreatic cancer researchers, who have organized investigative teams to develop highly interactive and synergistic research programs. The goal is to study the mechanisms, by which obesity promotes pancreatic cancer development and to explore interventional, cancerpreventing strategies. Innovative animal and cell culture models and novel concepts strongly supported by a wealth of preliminary data are proposed. The Projects will focus on: Adipose tissue inflammation in obesitypromoted pancreatic cancer (Project 1); Chemoprevention of pancreatic cancer with lipid-lowering and antidiabetic agents (Project 2); Role of the pancreatic fibro-inflammatory microenvironment in obesitypromoted pancreatic cancer (Project 3). The projects will utilize an Administrative Core (with Biostatistics SubCore) and a Shared Resource Core, the Animal and Cell Models Core (with Pathology Sub-Core). An External Advisory Board comprised of nationally and internationally recognized translational pancreatic cancer investigators and advocates has been assembled. The Program Project is designed for maximum integration and synergy of research and key investigators, who have been collaborating for more than 12 years so that the proposed Program can be focused on the most promising investigations with the greatest translational potential and impact.


  • Teper Y, Ye L, Waldron RT, Lugea A, Sun X, Sinnett-Smith J, Hines OJ, Pandol SJ, Rozengurt E, Eibl G. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Scientific reports. 2023 Sep 26;13(1):16144. PMID: 37752238
  • Zhou W, Lim A, Edderkaoui M, Osipov A, Wu H, Wang Q, Pandol S. Role of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer. International journal of biological sciences. 2024 Jan 1;20(1):15-28. doi: 10.7150/ijbs.83586. eCollection 2024. PMID: 38164167